Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1988 1
1990 1
1994 2
1995 4
1996 4
1997 1
1999 3
2000 3
2001 2
2002 4
2003 2
2004 4
2005 11
2006 9
2007 13
2008 14
2009 35
2010 25
2011 28
2012 24
2013 53
2014 69
2015 84
2016 72
2017 65
2018 63
2019 89
2020 94
2021 113
2022 135
2023 9
Text availability
Article attribute
Article type
Publication date

Search Results

939 results
Results by year
Filters applied: . Clear all
Page 1
Targeting MET Dysregulation in Cancer.
Recondo G, Che J, Jänne PA, Awad MM. Recondo G, et al. Among authors: che j. Cancer Discov. 2020 Jul;10(7):922-934. doi: 10.1158/2159-8290.CD-19-1446. Epub 2020 Jun 12. Cancer Discov. 2020. PMID: 32532746 Free PMC article. Review.
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development.
Donovan KA, Ferguson FM, Bushman JW, Eleuteri NA, Bhunia D, Ryu S, Tan L, Shi K, Yue H, Liu X, Dobrovolsky D, Jiang B, Wang J, Hao M, You I, Teng M, Liang Y, Hatcher J, Li Z, Manz TD, Groendyke B, Hu W, Nam Y, Sengupta S, Cho H, Shin I, Agius MP, Ghobrial IM, Ma MW, Che J, Buhrlage SJ, Sim T, Gray NS, Fischer ES. Donovan KA, et al. Among authors: che j. Cell. 2020 Dec 10;183(6):1714-1731.e10. doi: 10.1016/j.cell.2020.10.038. Epub 2020 Dec 3. Cell. 2020. PMID: 33275901 Free article.
Discovery and resistance mechanism of a selective CDK12 degrader.
Jiang B, Gao Y, Che J, Lu W, Kaltheuner IH, Dries R, Kalocsay M, Berberich MJ, Jiang J, You I, Kwiatkowski N, Riching KM, Daniels DL, Sorger PK, Geyer M, Zhang T, Gray NS. Jiang B, et al. Among authors: che j. Nat Chem Biol. 2021 Jun;17(6):675-683. doi: 10.1038/s41589-021-00765-y. Epub 2021 Mar 22. Nat Chem Biol. 2021. PMID: 33753926 Free PMC article.
Robotic-assisted Versus Video-assisted Thoracoscopic Lobectomy: Short-term Results of a Randomized Clinical Trial (RVlob Trial).
Jin R, Zheng Y, Yuan Y, Han D, Cao Y, Zhang Y, Li C, Xiang J, Zhang Z, Niu Z, Lerut T, Lin J, Abbas AE, Pardolesi A, Suda T, Amore D, Schraag S, Aigner C, Li J, Che J, Hang J, Ren J, Zhu L, Li H. Jin R, et al. Among authors: che j. Ann Surg. 2022 Feb 1;275(2):295-302. doi: 10.1097/SLA.0000000000004922. Ann Surg. 2022. PMID: 33938492 Clinical Trial.
Altered pathways and targeted therapy in double hit lymphoma.
Zhuang Y, Che J, Wu M, Guo Y, Xu Y, Dong X, Yang H. Zhuang Y, et al. Among authors: che j. J Hematol Oncol. 2022 Mar 18;15(1):26. doi: 10.1186/s13045-022-01249-9. J Hematol Oncol. 2022. PMID: 35303910 Free PMC article. Review.
The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
Yang G, Wang J, Tan L, Munshi M, Liu X, Kofides A, Chen JG, Tsakmaklis N, Demos MG, Guerrera ML, Xu L, Hunter ZR, Che J, Patterson CJ, Meid K, Castillo JJ, Munshi NC, Anderson KC, Cameron M, Buhrlage SJ, Gray NS, Treon SP. Yang G, et al. Among authors: che j. Blood. 2021 Nov 18;138(20):1966-1979. doi: 10.1182/blood.2021011405. Blood. 2021. PMID: 34132782 Free PMC article.
Traditional Chinese medicine shenhuang granule in patients with severe/critical COVID-19: A randomized controlled multicenter trial.
Zhou S, Feng J, Xie Q, Huang T, Xu X, Zhou D, Zhang W, Sun S, Liu X, Wu X, Che J, Fan T, Zou D, Wang J, Zhan D, Peng D, Feng Y, Yu G, Yuan Z, Fang B. Zhou S, et al. Among authors: che j. Phytomedicine. 2021 Aug;89:153612. doi: 10.1016/j.phymed.2021.153612. Epub 2021 May 28. Phytomedicine. 2021. PMID: 34126419 Free PMC article. Clinical Trial.
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Recondo G, Bahcall M, Spurr LF, Che J, Ricciuti B, Leonardi GC, Lo YC, Li YY, Lamberti G, Nguyen T, Milan MSD, Venkatraman D, Umeton R, Paweletz CP, Albayrak A, Cherniack AD, Price KS, Fairclough SR, Nishino M, Sholl LM, Oxnard GR, Jänne PA, Awad MM. Recondo G, et al. Among authors: che j. Clin Cancer Res. 2020 Jun 1;26(11):2615-2625. doi: 10.1158/1078-0432.CCR-19-3608. Epub 2020 Feb 7. Clin Cancer Res. 2020. PMID: 32034073
939 results